Synthetic Lung Surfactant Treatment for COVID-19 Pneumonia

Title:Synthetic Lung Surfactant Treatment for COVID-19 Pneumonia

Volume: 2 Issue: 1

Author(s): Frans J. Walther*Alan J. Waring

Affiliation:

• Departments of Pediatrics and Internal Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA & The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California,United States

Keywords: lung surfactant, alveolar type 2 cells, respiratory failure, SARS-CoV-2, COVID-19, pneumonia.

Abstract: COVID-19 has led to morbidity in millions of patients, ranging from mild flu-like symptoms to severe respiratory failure, necessitating oxygen supplementation and mechanical ventilation, and ultimately death. The SARS-CoV-2 virus reacts with angiotensin-converting enzyme 2 (ACE2) molecules that are especially found in alveolar epithelial type 2 cells in the lungs and thereby causes a loss in lung surfactant, a protein-lipid mixture that is crucial for both native immunity and reduction of surface tension in the lung alveoli. Lung surfactant insufficiency results in atelectasis and loss of functional lung tissue amid an inflammatory storm and may be countered by treating COVID-19 pneumonia patients with exogenous lung surfactant, preferably by aerosol delivery of a novel dry powder synthetic lung surfactant. More research on timing, dosing, and delivery of synthetic lung surfactant in patients with COVID-19 pneumonia is of crucial importance to implement this approach in clinical practice.

Cite this article as:

Walther J. Frans *, Waring J. Alan , Synthetic Lung Surfactant Treatment for COVID-19 Pneumonia, Coronaviruses 2021; 2 (1) : e160223186890 . https://dx.doi.org/10.2174/2666796701999201014160428